ArriVent BioPharma击败了对Q4收入的估算,增加了其库存,吸引了升级和增加投资。 ArriVent BioPharma beat Q4 earnings estimates, boosting its stock and attracting upgrades and increased investment.

ArriveVent BioPharma(AVBP)报告说,2026年3月5日的Q4收入比预期的要好,调整后的每股损失为0.78美元,击败估计数为0.09美元。 ArriVent BioPharma (AVBP) reported better-than-expected Q4 earnings on March 5, 2026, with an adjusted loss of $0.78 per share, beating estimates by $0.09. 这股股票在3月14日交易23.90美元, 多个公司提升了评级, 包括BTIG将目标提高到50美元, The stock, trading at $23.90 on March 14, saw multiple firms upgrade ratings, including BTIG raising its target to $50.00 and assigning a "Strong-Buy" rating. Suvretta资本管理公司的股份增加了8.5%,达到370万股,目前价值为6 830万美元。 Suvretta Capital Management increased its stake by 8.5% to 3.7 million shares, now valued at $68.3 million. 该公司开发用于非小型细胞肺癌的Furmonertinib,市场上限为10.6亿美元,协商一致的“Moderate Buy”评级为40.78美元的平均价格目标。 The company, developing Furmonertinib for non-small cell lung cancer, has a market cap of $1.06 billion and a consensus "Moderate Buy" rating with a $40.78 average price target.